Creative Biolabs is one of the forward-looking companies as well as undisputed market leader delivering impeccable services to customers all over the world. Currently, we offer this exclusive opportunity for our worldwide clients to adopt the most comprehensive ADCC assay service.
There are plenty of sophisticated mechanisms in the human immune system to identify and eliminate unwanted cells (e.g., viral infection and tumor). Amongst these, antibody-dependent cellular cytotoxicity, namely ADCC, plays a crucial role. After an antibody selectively coats the opsonized target cell, effector immune cells, such as natural killer (NK) cells, recognize and bind the Fc portion of the antibody, activating the effector cells to lyse the target eventually. ADCC represents one vital adaptive immune defense from infections or tumorigenesis in vivo. It is also considered as one of the most important mechanism-of-actions (MOAs) for therapeutic antibodies. Marketed therapeutic antibody products can deliver their clinical efficacy by induction of ADCC as the primary mechanism, or have such potential as their secondary or tertiary MOA. Therefore, to determine the exact ADCC liability and subsequent measurement, if present, constitutes an imperative step in the development and functional characterization of antibody therapies.
Fig.1 Significant differences among the ADCC examinations.1, 2
Equipped with world-class technologies and seasoned team of experts, Creative Biolabs has developed, optimized, and validated an integrated ADCC evaluation platform. We provide multiple assay formats, from which you can select the best fit for your specific project.
We can deal with frozen cells from customers upon request. In case you haven't got an ideal target cell line, you can rely on our extensive expertise to find the most appropriate one. There are over a hundred well-qualified tumor cell lines available at Creative Biolabs. Our scientists also have vast experience in designing a variety of disease models for in vivo pharmacology research.
NK cell is the major effector immune cell involved in ADCC, which can interact with Fc portions of IgGs via Fc receptor, mostly FcγRIIIa (CD16a) on its surface. Notably, human FcγRIIIa displays a dimorphism in the position of residue 158, resulting in a higher affinity variant (V variant) and a lower affinity variant (F variant). Given the essential role of effector cells in ADCC, Creative Biolabs provides multiple choices for best assay performance.
Based on unparalleled technologies and abundant resources, this robust and reliable ADCC test system of Creative Biolabs not only guarantees the most accurate and reproducible outcomes but also accommodates any custom experimental designs. Our highly specific assays can offer absolute confidence in evaluating clinical effects and risk potentials concerning ADCC activity.
Besides, Creative Biolabs also offers complement-dependent cellular cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP) for investigating the antibodies’ mechanism of action (MOA), as well as to ensure efficacy and safety.
For more detailed information, please feel free to contact us or directly sent us an inquiry.
References
For Research Use Only.